Human Factors: Training and SME Coaching for E&L Defenses


Human Factors: Training and SME Coaching for E&L Defenses

Published on 10/12/2025

Human Factors: Training and SME Coaching for E&L Defenses

Introduction to Extractables and Leachables (E&L)

The pharmaceutical industry faces increasing scrutiny regarding the safety and efficacy of drug products, specifically the impact of extractables and leachables (E&L) from packaging materials and device components. This article serves as a comprehensive guide for pharmaceutical professionals on effectively managing E&L risks through training, human factors, and subject matter expert (SME) coaching. Understanding the concepts and implementing systematic practices is essential for achieving compliance with regulatory requirements from bodies such as the FDA, EMA, and MHRA.

As drug formulation and delivery systems evolve, particularly with the rise of single-use systems, the significance of E&L evaluation has also grown. The challenges include ensuring container closure integrity (CCI) and demonstrating compliance with industry benchmarks set in guidelines like the USP and EU GMP Annex 1. This article will explore best practices for an effective E&L risk assessment and the integration of human factors into the training process.

Step 1: Understanding the Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT)

The first step in E&L management is the identification of the analytical evaluation threshold (AET) and the dose-based threshold (DBT). These thresholds help define acceptable levels of E&L based on safety and regulatory expectations.

The AET is a scientifically derived concentration above which extractables should be quantitatively evaluated. The AET calculation hinges on several factors, such as the overall daily dose of the drug product, the material’s exposure duration, and the toxicity data available for the leachables.

  • Calculate the AET: Typically, the AET can be calculated using the formula:
  • AET = (Toxicity Reference Value) / (Daily Dose)

DBT rather refers to the concentration of leachables that can be tolerated based on their potential toxicological effects. The DBT should reflect a level that guarantees consumer safety, often demanding a more detailed toxicological profile than the AET.

Challenges in AET and DBT Calculation

The calculations for AET and DBT can vary widely based on various parameters including:

  • Type of drug substance
  • Intended patient population
  • Formulation chemistry
  • Packaging materials used

To mitigate challenges, sites should engage with toxicologists and leverage resources from regulatory guidelines such as the PQRI guideline for comprehensive insight on E&L assessments.

Step 2: Training and Human Factors Considerations

Training is a critical component of developing a strong E&L compliance framework. Introducing the concept of human factors in training sessions helps professionals grasp why and how E&L evaluations influence drug safety in real-world scenarios. Effective training will incorporate practical workshops, case studies, and scenario-based learning to promote engagement and retention.

Human factors engineering involves understanding how people interact with products and systems, thus impacting their performance in E&L evaluations. A well-trained workforce will enhance the efficacy of the E&L programs through careful evaluation of material interactions that can lead to extractables or leachables.

Key Training Components

  • Curriculum Development: Establish a curriculum that covers E&L fundamentals, risk assessments, legislation, and regulatory requirements, specifically tailored to different personnel roles.
  • Interactive Workshops: Promote practical learning experiences such as hands-on workshops on E&L testing techniques and methodologies.
  • Assessments: Regularly evaluate comprehension through quizzes and hands-on assessments to ensure understanding of E&L concepts and calculations.

Step 3: Subject Matter Expert (SME) Coaching

Incorporating SME coaching ensures that complex issues regarding E&L are addressed by knowledgeable individuals who can mentor and guide teams through intricate scenarios. SMEs play a pivotal role in training, focusing on insights derived from their extensive experience and specialized knowledge. The role of an SME is not only to provide knowledge but also to instill confidence in E&L management processes.

Implementing SME Coaching Programs

Effective SME coaching programs should include:

  • Mentorship Structures: Pair SME mentors with team members to facilitate one-on-one learning and address specific questions.
  • Knowledge Sharing Sessions: Organize regular meetings where SMEs can share insights, case studies, and latest research findings related to E&L.
  • Continuous Support: Ensure that SMEs are available for ongoing support, especially when teams are working through specific E&L evaluations or challenges.

Step 4: E&L Risk Assessment and Reporting

Conducting a thorough E&L risk assessment is crucial in identifying potential safety issues linked to extractables and leachables. The framework for risk assessment should adhere to existing regulatory guidelines, enabling the identification of risk factors through a systematic approach.

Risk Assessment Methodology

  • Identify Packaging Components: List all materials and components that interact with drug formulations.
  • Data Gathering: Utilize existing data from previous studies, supplier information, and literature related to extractables.
  • Risk Evaluation: Classify the risks according to their severity, likelihood, and potential impact on drug product quality.

Executive roles should review assessments and reports to ensure adherence to compliance with industry standards and regulatory bodies. Use of tools like Failure Mode and Effects Analysis (FMEA) can provide a structured approach to risk prioritization during the assessment process.

Step 5: Validation of Single-Use Systems

With the increasing reliance on single-use systems validation, it is essential to ensure that these systems are appropriately assessed for E&L. Validation activities should include comprehensive studies to substantiate the safety and quality of the drug product in contact with single-use materials.

Key Aspects of Validation

  • Material Selection: Select materials that comply with relevant regulatory requirements, such as USP class standards.
  • Characterization Studies: Conduct studies that demonstrate the material’s extractables profile under representative conditions.
  • Standard Operating Procedures: Develop SOPs that outline the validation processes, responsibilities, and documentation requirements.

Regular audits should be divided between internal evaluations of the E&L processes and third-party assessments, ensuring ongoing compliance and improvement of the single-use systems.

Conclusion: Path Forward for E&L Defenses

As pharmaceutical professionals, it is crucial to acknowledge the evolving landscape of E&L management. Emphasizing the importance of human factors, robust training programs, and SME coaching will underpin defensible practices regarding extractables and leachables.

By keeping abreast of the ever-changing regulatory environment, engaging with relevant guidelines issued by the EMA and adhering to the best practices outlined, organizations will enhance their overall quality systems and maintain compliance. As E&L evaluation remains vital for packaging qualification, it is imperative that professionals take these steps seriously to underpin product safety and integrity.